P0749 Infection adverse events with tulisokibart over 50 weeks of treatment in the phase 2 Crohn’s disease APOLLO-CD trial

João Sabino(KU Leuven), B G Feagan(Western University), Bin Dong(Merck & Co., Inc., Rahway, NJ, USA (United States)), Wei Zhou(Broad Institute), B E Sands(Icahn School of Medicine at Mount Sinai), L Peyrin-Biroulet(Inserm), Mark Yen(Merck & Co., Inc., Rahway, NJ, USA (United States))
Journal of Crohn s and Colitis
January 1, 2025
10.1093/ecco-jcc/jjae190.0923
Cited by 1

Related Papers

A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis
|Gut|2013|1.9k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
|Journal of Crohn s and Colitis|2019|1.4k
ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment
|Journal of Crohn s and Colitis|2019|1.1k
ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment
|Journal of Crohn s and Colitis|2024|338